These numbers are similar to a recent publication of 2579 ‘pan‐gynecologic cancer’ patients (1087 breast cancers, 579 ovarian cancers, 548 endometrial cancers, 308 cervical cancers, and 57 uterine carcinosarcomas) in The Cancer Genome Atlas; they reported TP53 and PIK3CA alteration rates of 44% and 32%, respectively [14]. The gene discussed is TP53; the disease is ovarian cancer.